Table 5: Barriers to suppressed repeat viral load in adolescent participants at CHE.
|
Variable |
Suppressed VL n (%) |
High VL n (%) |
RR |
CI |
p-value |
|
Mean age |
15.32 ± 2.621 |
13.90 ± 2.367 |
3.301 |
0.567-2.263 |
0.001 |
|
Gender |
|||||
|
Male |
33 (44.0) |
30 (47.6) |
0.935 |
0.687-1.274 |
0.8 |
|
Female |
42 (56.0) |
33 (52.4) |
|
|
|
|
Number of EAC Sessions |
3.16 ± 0.546 |
3.05 ± 0.792 |
0.982 |
0.114-0.339 |
0.028 |
|
Duration in support group |
7.88 ± 3.650 |
5.18 ± 2.113 |
2.698 |
1.347-4.050 |
0.001 |
|
First viral load* |
7994 (2737-25268) |
19731 (10142-57641) |
3.54 |
|
0.001 |
|
Opportunistic infections |
|||||
|
Yes |
21 (28.0) |
9 (14.3) |
1.4 |
1.036-1.891 |
0.082 |
|
No |
54 (72.0) |
54 (85.7) |
|
|
|
|
ART regimen |
|||||
|
1st line |
66 (88.0) |
57 (90.5) |
0.894 |
0.573-1.395 |
0.642 |
|
2nd line |
9 (12.0) |
6 (9.5) |
|
|
|
|
WHO staging at initiation |
|||||
|
Stage 1 |
36 (48.0) |
33 (52.4) |
0.923 |
0.679-1.254 |
0.733 |
|
Stage 2 |
21 (28.0) |
24 (38.1) |
0.804 |
0.562-1.148 |
0.281 |
|
Stage 3 |
12 (16.0) |
6 (33.3) |
1.27 |
0.879-1.835 |
0.383 |
|
Stage 4 |
6 (8.0) |
0 (0.0) |
/ |
/ |
0.031 |
*Median